{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:11:55Z","timestamp":1761858715325,"version":"build-2065373602"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngologic Clinics of North America"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.otc.2021.12.004","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T17:18:05Z","timestamp":1646414285000},"page":"287-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-surgical Interventions for Pituitary Lesions"],"prefix":"10.1016","volume":"55","author":[{"given":"Nisha","family":"Suda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib1","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary","volume":"112","author":"Melmed","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.otc.2021.12.004_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-010-0290-z","article-title":"Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis","volume":"14","author":"dos Santos Nunes","year":"2011","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib4","first-page":"382","article-title":"Pituitary-tumor endocrinopathies","author":"Melmed","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib5","doi-asserted-by":"crossref","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"BEVAN","year":"1992","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib6","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-18-0682","article-title":"Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas","volume":"180","author":"Ioachimescu","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib7","doi-asserted-by":"crossref","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma","volume":"87","author":"Gillam","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"13","key":"10.1016\/j.otc.2021.12.004_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21639","article-title":"Meta-analysis of heart valve abnormalities in Parkinson\u2019s disease patients treated with dopamine agonists","volume":"22","author":"Simonis","year":"2007","journal-title":"Movement Disord"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2362.2011.02520.x","article-title":"Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status","volume":"41","author":"McCormack","year":"2011","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib11","article-title":"Functioning pituitary adenomas \u2013 current treatment options and emerging medical therapies","volume":"15","author":"Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib12","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib13","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-020-01091-7","article-title":"A\u00a0Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"24","key":"10.1016\/j.otc.2021.12.004_bib14","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra062453","article-title":"Acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib15","article-title":"Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study","volume":"31","author":"Auriemma","year":"2008","journal-title":"J\u00a0Endocrinol Invest"},{"key":"10.1016\/j.otc.2021.12.004_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol"},{"issue":"3","key":"10.1016\/j.otc.2021.12.004_bib17","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol"},{"issue":"9","key":"10.1016\/j.otc.2021.12.004_bib19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A\u00a0consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib21","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib22","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.otc.2021.12.004_bib23","doi-asserted-by":"crossref","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connections"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib24","doi-asserted-by":"crossref","DOI":"10.1186\/s12902-020-0545-2","article-title":"Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib25","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib26","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-16-0697","article-title":"Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis","volume":"176","author":"Tritos","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib27","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib29","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib30","doi-asserted-by":"crossref","DOI":"10.1507\/endocrj.EJ12-0272","article-title":"Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature","volume":"60","author":"Suda","year":"2013","journal-title":"Endocr J"},{"issue":"12","key":"10.1016\/j.otc.2021.12.004_bib31","article-title":"2019 update on TSH-secreting pituitary adenomas","volume":"42","author":"Beck-Peccoz","year":"2019","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib32","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-07-0098","article-title":"Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature","volume":"157","author":"Kienitz","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib33","article-title":"Cushing\u2019s disease","volume":"8","author":"Nishioka","year":"2019","journal-title":"J\u00a0Clin Med"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib34","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12\u00a0month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.otc.2021.12.004_bib36","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-015-0557-2","article-title":"The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center","volume":"50","author":"Simeoli","year":"2015","journal-title":"Endocrine"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-019-00984-6","article-title":"Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: interim results from a long-term real-world evidence study","volume":"22","author":"Manetti","year":"2019","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib38","doi-asserted-by":"crossref","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing\u2019s disease","volume":"36","author":"Pivonello","year":"2015","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib39","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.otc.2021.12.004_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.otc.2021.12.004_bib41","doi-asserted-by":"crossref","DOI":"10.1080\/14656566.2021.1897106","article-title":"Osilodrostat for the treatment of Cushing\u2019s disease","volume":"22","author":"Rasool","year":"2021","journal-title":"Expert Opin Pharmacother"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib42","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"10.1016\/j.otc.2021.12.004_bib43","article-title":"Metyrapone treatment in endogenous Cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s40267-020-00799-7","article-title":"Ketoconazole in Cushing\u2019s syndrome: a profile of its use","volume":"37","author":"Shirley","year":"2021","journal-title":"Drugs Ther Perspect"},{"issue":"6","key":"10.1016\/j.otc.2021.12.004_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib46","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.otc.2021.12.004_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.otc.2021.12.004_bib48","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM197903013000903","article-title":"Treatment of Cushing\u2019s disease by O,p\u2032DDD. Survey of 62 cases","volume":"300","author":"Luton","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib49","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-12-0274","article-title":"Therapy in endocrine disease: etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.otc.2021.12.004_bib50","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib51","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib52","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-019-00960-0","article-title":"Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management","volume":"22","author":"Esposito","year":"2019","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/j.otc.2021.12.004_bib53","article-title":"New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist","volume":"76","author":"McGrath","year":"1993","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib54","doi-asserted-by":"crossref","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.otc.2021.12.004_bib55","doi-asserted-by":"crossref","unstructured":"Chanson P, Lecoq A-L, Raverot G, et\u00a0al. Physiopathology, diagnosis, and treatment of nonfunctioning pituitary adenomas. In: ; 2018. doi:10.1007\/978-3-319-44444-4_4.","DOI":"10.1007\/978-3-319-44444-4_4"},{"key":"10.1016\/j.otc.2021.12.004_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.otc.2021.12.004_bib57","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-2031","article-title":"Pituitary carcinoma: difficult diagnosis and treatment","volume":"96","author":"Heaney","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.otc.2021.12.004_bib58","doi-asserted-by":"crossref","DOI":"10.1385\/ENDO:28:1:027","article-title":"Classification and pathology of pituitary tumors","volume":"28","author":"Kontogeorgos","year":"2005","journal-title":"Endocrine"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","article-title":"Pituitary carcinoma","volume":"79","author":"Pernicone","year":"1997","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.otc.2021.12.004_bib60","doi-asserted-by":"crossref","DOI":"10.1210\/jcem.83.12.5300","article-title":"The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors","volume":"83","author":"Kaltsas","year":"1998","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.otc.2021.12.004_bib61","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neuro-Oncology Pract"},{"issue":"3","key":"10.1016\/j.otc.2021.12.004_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/neuros\/nyy178","article-title":"Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study","volume":"84","author":"Ding","year":"2019","journal-title":"Neurosurgery"},{"issue":"10","key":"10.1016\/j.otc.2021.12.004_bib63","doi-asserted-by":"crossref","DOI":"10.1007\/s00701-007-1253-7","article-title":"Gamma knife radiosurgery for endocrine-inactive pituitary adenomas","volume":"149","author":"Li\u0161\u010d\u00e1k","year":"2007","journal-title":"Acta Neurochirurgica"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2019.101290","article-title":"The epidemiology, diagnosis and treatment of prolactinomas: the old and the new","volume":"33","author":"Chanson","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.otc.2021.12.004_bib65","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-4376","article-title":"Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation","volume":"99","author":"Malchiodi","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.otc.2021.12.004_bib66","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2005-1616","article-title":"Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly","volume":"91","author":"Jenkins","year":"2006","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.otc.2021.12.004_bib67","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-014-0615-4","article-title":"Update on radiation therapy in patients with Cushing\u2019s disease","volume":"18","author":"Tritos","year":"2015","journal-title":"Pituitary"},{"issue":"8","key":"10.1016\/j.otc.2021.12.004_bib68","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Otolaryngologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521002401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0030666521002401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T14:54:55Z","timestamp":1758466495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0030666521002401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0030666521002401"],"URL":"https:\/\/doi.org\/10.1016\/j.otc.2021.12.004","relation":{},"ISSN":["0030-6665"],"issn-type":[{"type":"print","value":"0030-6665"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-surgical Interventions for Pituitary Lesions","name":"articletitle","label":"Article Title"},{"value":"Otolaryngologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.otc.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}